mTOR Pathway Expression as Potential Predictive Biomarker in Patients with Advanced Neuroendocrine Tumors Treated with Everolimus

Background. Everolimus (Eve), which is a mammalian target of Rapamicin (mTOR) inhibitor, is part of the therapeutic armamentarium of neuroendocrine tumors (NETs). Currently, there are no validated biomarkers predicting Eve efficacy in NETs. In this study, we explore whether the expression of phospho...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancers (Basel)
Asıl Yazarlar: Gelsomino, Fabio, Casadei-Gardini, Andrea, Caputo, Francesco, Rossi, Giulio, Bertolini, Federica, Petrachi, Tiziana, Spallanzani, Andrea, Pettorelli, Elisa, Kaleci, Shaniko, Luppi, Gabriele
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: MDPI 2020
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7281483/
https://ncbi.nlm.nih.gov/pubmed/32397669
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12051201
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller